Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2003;108:1027-1033
Published online before print August 11, 2003, doi: 10.1161/01.CIR.0000085066.05180.40
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
108/8/1027    most recent
01.CIR.0000085066.05180.40v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Di Diego, J. M.
Right arrow Articles by Antzelevitch, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Di Diego, J. M.
Right arrow Articles by Antzelevitch, C.
Related Collections
Right arrow Electrophysiology
Right arrow Arrythmias-basic studies

(Circulation. 2003;108:1027.)
© 2003 American Heart Association, Inc.


Basic Science Reports

Cisapride-Induced Transmural Dispersion of Repolarization and Torsade de Pointes in the Canine Left Ventricular Wedge Preparation During Epicardial Stimulation

José M. Di Diego, MD; Luiz Belardinelli, MD; Charles Antzelevitch, PhD

From Masonic Medical Research Laboratory (J.M.D., C.A.), Utica, NY, and CV Therapeutics, Inc (L.B.), Palo Alto, Calif.

Correspondence to Dr Charles Antzelevitch, Gordon K. Moe Scholar, Executive Director, Masonic Medical Research Laboratory, 2150 Bleecker St, Utica, NY 13501-1787. E-mail ca{at}mmrl.edu

Received March 18, 2003; revision received May 5, 2003; accepted May 5, 2003.

Background— Cisapride, a gastrointestinal prokinetic agent, was recently withdrawn from the market because of its propensity to induce torsade de pointes (TdP) arrhythmias. The present study examines the electrophysiological actions of cisapride in the isolated arterially perfused canine left ventricular wedge preparation.

Methods and Results— Transmembrane action potentials from epicardial and M regions and a pseudo-ECG were simultaneously recorded. Cisapride (0.1 to 5 µmol/L) was added to the coronary perfusate. Cisapride prolonged the QT interval and increased transmural dispersion of repolarization (TDR) at relatively low but not at high concentrations. TdP could be induced with programmed electrical stimulation only at a low concentration of drug (0.2 µmol/L), when TDR was maximally prolonged. Moreover, TdP could only be induced during epicardial (but not endocardial) activation of the wedge, which was found to augment TDR. At higher concentrations of cisapride, QT was further prolonged, TDR was diminished, and TdP could no longer be induced. Tpeak–Tend interval and Tpeak–Tend area provided reasonable electrocardiographic indices of TDR.

Conclusion— Our data (1) demonstrate a biphasic concentration/response relationship for the effect of cisapride to induce long-QT syndrome and TdP, (2) show the value of the left ventricular wedge preparation in identifying drugs that pose an arrhythmic risk, (3) support the hypothesis that risk for development of TdP is related to the increase in TDR rather than to prolongation of the QT interval, and (4) indicate that epicardial activation of the left ventricle, as occurs during biventricular pacing, can facilitate the development of TdP under long-QT conditions.


Key Words: long-QT syndrome • arrhythmias • drugs • ventricles • pacing




This article has been cited by other articles:


Home page
EuropaceHome page
P. Dilaveris, G. Giannopoulos, A. Synetos, C. Aggeli, L. Raftopoulos, P. Arsenos, K. Gatzoulis, and C. Stefanadis
Effect of biventricular pacing on ventricular repolarization and functional indices in patients with heart failure: lack of association with arrhythmic events
Europace, June 1, 2009; 11(6): 741 - 750.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. Stoll, M. Quentin, A. Molojavyi, V. Thamer, and U. K.M. Decking
Spatial heterogeneity of myocardial perfusion predicts local potassium channel expression and action potential duration
Cardiovasc Res, February 1, 2008; 77(3): 489 - 496.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
L. Wu, S. Rajamani, J. C. Shryock, H. Li, J. Ruskin, C. Antzelevitch, and L. Belardinelli
Augmentation of late sodium current unmasks the proarrhythmic effects of amiodarone
Cardiovasc Res, February 1, 2008; 77(3): 481 - 488.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. M. Cordeiro, J. E. Malone, J. M. Di Diego, F. S. Scornik, G. L. Aistrup, C. Antzelevitch, and J. A. Wasserstrom
Cellular and subcellular alternans in the canine left ventricle
Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3506 - H3516.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
C. Antzelevitch
Role of spatial dispersion of repolarization in inherited and acquired sudden cardiac death syndromes
Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2024 - H2038.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
C. Antzelevitch
Ionic, molecular, and cellular bases of QT-interval prolongation and torsade de pointes
Europace, September 1, 2007; 9(suppl_4): iv4 - iv15.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
K. Ahmad and P. Dorian
Drug-induced QT prolongation and proarrhythmia: an inevitable link?
Europace, September 1, 2007; 9(suppl_4): iv16 - iv22.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
E. L. Strevel, D. J. Ing, and L. L. Siu
Molecularly Targeted Oncology Therapeutics and Prolongation of the QT Interval
J. Clin. Oncol., August 1, 2007; 25(22): 3362 - 3371.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
I. N. Sabir, M. J. Killeen, C. A. Goddard, G. Thomas, S. Gray, A. A. Grace, and C. L.-H. Huang
Transient alterations in transmural repolarization gradients and arrhythmogenicity in hypokalaemic Langendorff-perfused murine hearts
J. Physiol., May 15, 2007; 581(1): 277 - 289.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
R. Bai, X. Y. Yang, Y. Song, L. Lin, J. G. Lu, C. K. Ching, J. Pu, R. Kam, L. F. Hsu, C. T. Zhang, et al.
Impact of left ventricular epicardial and biventricular pacing on ventricular repolarization in normal-heart individuals and patients with congestive heart failure.
Europace, November 1, 2006; 8(11): 1002 - 1010.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
A. Kijtawornrat, Y. Nishijima, B. M. Roche, B. W. Keene, and R. L. Hamlin
Use of a Failing Rabbit Heart as a Model to Predict Torsadogenicity
Toxicol. Sci., September 1, 2006; 93(1): 205 - 212.
[Abstract] [Full Text] [PDF]


Home page
PhysiologyHome page
T. Jespersen, M. Grunnet, and S.-P. Olesen
The KCNQ1 Potassium Channel: From Gene to Physiological Function
Physiology, December 1, 2005; 20(6): 408 - 416.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
C. Antzelevitch
Cardiac repolarization. The long and short of it
Europace, January 1, 2005; 7(s2): S3 - S9.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
C. Antzelevitch, L. Belardinelli, A. C. Zygmunt, A. Burashnikov, J. M. Di Diego, J. M. Fish, J. M. Cordeiro, and G. Thomas
Electrophysiological Effects of Ranolazine, a Novel Antianginal Agent With Antiarrhythmic Properties
Circulation, August 24, 2004; 110(8): 904 - 910.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
N. Ueda, D. P Zipes, and J. Wu
Prior ischemia enhances arrhythmogenicity in isolated canine ventricular wedge model of long QT 3
Cardiovasc Res, July 1, 2004; 63(1): 69 - 76.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
H. Ashikaga, J. H. Omens, N. B. Ingels Jr., and J. W. Covell
Transmural mechanics at left ventricular epicardial pacing site
Am J Physiol Heart Circ Physiol, June 1, 2004; 286(6): H2401 - H2407.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
B. R. Chaitman
Efficacy and Safety of a Metabolic Modulator Drug in Chronic Stable Angina: Review of Evidence from Clinical Trials
Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2004; 9(1_suppl): S47 - S64.
[Abstract] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
C. Antzelevitch, L. Belardinelli, L. Wu, H. Fraser, A. C. Zygmunt, A. Burashnikov, J. M. Di Diego, J. M. Fish, J. M. Cordeiro, R. J. Goodrow Jr, et al.
Electrophysiologic Properties and Antiarrhythmic Actions of a Novel Antianginal Agent
Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2004; 9(1_suppl): S65 - S83.
[Abstract] [PDF]


Home page
JAMAHome page
B. R. Chaitman, C. J. Pepine, J. O. Parker, J. Skopal, G. Chumakova, J. Kuch, W. Wang, S. L. Skettino, and A. A. Wolff
Effects of Ranolazine With Atenolol, Amlodipine, or Diltiazem on Exercise Tolerance and Angina Frequency in Patients With Severe Chronic Angina: A Randomized Controlled Trial
JAMA, January 21, 2004; 291(3): 309 - 316.
[Abstract] [Full Text] [PDF]